# Fred Yang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fred-yang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,049 |
| Field | Diabetes Treatment and Management |
| h-index | 10 |
| i10-index | 10 |
| OpenAlex ID | https://openalex.org/A5110475866 |
| Works | 23 |

## Researcher papers

- [Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes](https://scholariq.org/papers/potential-of-albiglutide-a-long-acting-glp-1-receptor-agonist-in-type-2-diabetes/)
- [HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin](https://scholariq.org/papers/harmony-3-104-week-randomized-double-blind-placebo-and-active-controlled-trial/)
- [Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro](https://scholariq.org/papers/advancing-basal-insulin-replacement-in-type-2-diabetes-inadequately-controlled/)
- [Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise](https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-glp-1-receptor-agonist-albiglutide-harmony-2/)
- [Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study](https://scholariq.org/papers/efficacy-and-safety-of-the-once-weekly-glp-1-receptor-agonist-albiglutide-versus/)
- [Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus](https://scholariq.org/papers/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-albiglutide-a-long/)
- [Beware of on-treatment safety analyses](https://scholariq.org/papers/beware-of-on-treatment-safety-analyses/)
- [Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide](https://scholariq.org/papers/effect-of-renal-impairment-on-the-pharmacokinetics-efficacy-and-safety-of/)
- [The third-generation tetracycline, KBP-7072, exploits and reveals a new potential of the primary tetracycline binding pocket](https://scholariq.org/papers/the-third-generation-tetracycline-kbp-7072-exploits-and-reveals-a-new-potential/)
- [Multiple Ascending Dose Safety, Tolerability, and Pharmacokinetics of KBP-7072, a Novel Third-generation Tetracycline](https://scholariq.org/papers/multiple-ascending-dose-safety-tolerability-and-pharmacokinetics-of-kbp-7072-a/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.